| INTRODUCTION
Myxomatous mitral valve disease (MMVD) is the commonest cause of acquired heart disease in dogs 1,2 often resulting in congestive heart failure (CHF) and eventual cardiac-related death. 3, 4 Median survival times after the onset of CHF range widely based on treatment, but are typically less than 1 year. [5] [6] [7] Standardized medical treatment recommendations for dogs with CHF are based on clinical trial results and consensus opinion [7] [8] [9] ; however, decisions regarding dosing and dose adjustments, especially of diuretic medications, in individual dogs are made on a case-by-case basis and often rely on subjective criteria and the clinical acumen of the clinician. It is possible that the application of more objective criteria would allow for optimization of medical treatment in a greater proportional of dogs, potentially improving survival times.
Abbreviations: ACE, angiotensin converting enzyme; BUN, blood urea nitrogen; CHF, congestive heart failure; CI, confidence interval; ECG, electrocardiography; LA:Ao, ratio of left atrial to aortic root diameter; LVIDd, left ventricular internal dimension in diastole; LVIDDN, left ventricular internal dimension in diastole, normalized for body weight; LVIDs, left ventricular internal dimension in systole; LVIDSN, left ventricular internal dimension in systole, normalized for body weight; MMVD, myxomatous mitral valve disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; VHS, vertebral heart size Examples of objective criteria that might be of value in monitoring the effectiveness of medical treatment for CHF include circulating biomarkers such as N-terminal proB-type natriuretic peptide (NTproBNP). The hypothesis is that CHF treatment administered primarily to decrease NT-proBNP to a specified level results in decreased morbidity and case fatality. This hypothesis is appealing but controversial.
Recent meta-analyses involving many thousands of human patients indicated a benefit in morbidity 10 and case fatality, 11, 12 however important questions involving the optimal NT-proBNP level, nature of augmented treatment, cost effectiveness, and widespread use of biomarker-guided treatment remain. 13 In dogs with CHF secondary to MMVD, an observational study indicated that dogs with plasma NTproBNP concentrations <965 pmol/L 7-30 days after initial diagnosis of CHF had significantly longer cardiac survival times than those in which plasma NT-proBNP concentrations were ≥ 965 pmol/L, 14 suggesting the possibility that treatment to specifically lower NT-proBNP could improve survival. Despite previous trials in humans and observational data in dogs, whether NT-proBNP concentration can be reduced by escalation of medical treatment in dogs with CHF has not been previously reported. The aim of our study was to determine whether a prespecified therapeutic escalation algorithm would result in reductions in plasma NT-proBNP concentrations in dogs with stable CHF secondary to MMVD. 15 The lower and upper limits of detection of the NT-proBNP assay are 77 and 10 000 pmol/L, respectively. 15 Left and right lateral and dorsoventral thoracic radiographic projections were obtained. Vertebral heart size (VHS) was measured as previously described by a single observer (MJH). 
| MATERIALS AND METHODS

| RESULTS
Twenty-six dogs with CHF secondary to MMVD with a mean age of 11.1 ±2.1 years and a mean body weight of 7.31 ±3.07 kg were included in the study. Eleven male and 15 female dogs were recruited.
Mixed breeds were most frequently represented (n = 6), followed by Post hoc analysis demonstrated that Na + measurements were lower in group 1 compared with group 3 (P = .021) but did not differ between groups 1 and 2 or groups 2 and 3 (P = .52 and P = .088, respectively).
A flow diagram summarizing the evolution of assignments to groups 1-3 during the study is depicted in Figure 1 . No dog in any of the 3 groups required adjustments in treatment other than those that made were in accordance with the study algorithm. At visit 0, 8 dogs were assigned to group 1 and 12 dogs assigned to group 2. The NTproBNP measurement was not reported for 1 dog in group 1 at visit 1 due to an error at the commercial laboratory (the NT-proBNP measurement at visit 2 was available from this dog). Treatment intensification at visit 0 consisted of a 50% increase in furosemide dose Tricuspid regurgitation velocity (m/s) 3.1 ± 0. Normally distributed data are displayed as mean ± standard deviation. Non-normally distributed data are displayed as median (range). Abbreviations: ACE, angiotensin converting enzyme; BUN, blood urea nitrogen; K + , potassium; LA : Ao, left atrial to aortic ratio; LVIDDN, left ventricular internal dimension in diastole, normalized for body weight; LVISDN, left ventricular internal dimension in systole, normalized for body weight; NT-proBNP, N-terminal pro-B-type natriuretic peptide; Na + , sodium. 14 In this earlier study, NTproBNP was measured using the 1st-generation version of the ELISA, whereas measurements in our study were obtained using the 2nd-generation version of the assay, which is known to yield higher values compared with the 1st generation assay. 19 A scaling factor of 1.5 to achieve the threshold of 1500 pmol/L was derived by comparing cut-offs for differentiating cardiac from noncardiac causes of respiratory distress using the 1st-and 2nd-generation versions of the assay. 19, 20 In the aforementioned previous study, NT-proBNP concentration at time of active CHF was not found to be predictive of survival, suggesting that the NT-proBNP concentration achieved after resolution of CHF signs and during SC maintenance treatment was important. It remains unknown whether the achieved decrease in plasma NT-proBNP concentrations in our study would improve survival or reduce risk of SC episodes of CHF, and future randomized study of the effects of NT-proBNP lowering on morbidity and case fatality is appealing.
| DISCUSSION
Studies in human patients have used a variety of treatment escalation strategies including introduction or uptitration of loop and thiazide diuretics, ACE inhibitors, spironolactone, digoxin, beta-blockers, and inodilators. In some studies, a prespecified treatment escalation algorithm was followed 21, 22 while in other studies the attending clinician was instructed to escalate treatment according to their individual clinical judgment. [23] [24] [25] Our study used an empirical prespecified treatment escalation strategy that, included increasing existing doses of furosemide followed by introduction of thiazide diuretics and spironolactone, similar to the algorithms described in the aforementioned Finally, dogs of a variety of breeds were recruited and the groups were not balanced according to breed; this might have influenced the results of the study, as breed-specific differences in circulating NTproBNP concentrations in healthy dogs have been reported. 26 In conclusion, a prespecified treatment escalation algorithm reduces plasma NT-proBNP concentrations in dogs with clinically 
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